SPARC Sells Rare Pediatric Disease Priority Review Voucher for $195 Million After Sezaby Approval

SPARC will sell a Rare Pediatric Disease Priority Review Voucher for $195 million through an asset purchase agreement. The voucher was granted following the approval of Sezaby, a medication developed by SPARC.

The Priority Review Voucher program incentivizes the development of treatments for rare pediatric diseases. This voucher entitles the holder to priority review of a future New Drug Application, potentially shortening the approval timeline. SPARC obtained the voucher upon the FDA’s approval of Sezaby, and they have now decided to divest it through this sale.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 30, 2026

Author

GOAI